Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

The Handmaid's Tale is full of ostensibly harmless-sounding catchphrases whose entire meaning only reveals itself when read ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...